Mission

Mission & Values

FOCUSED ON ADVANCING GENETIC MEDICINES FOR RARE NEUROMUSCULAR AND CARDIAC DISEASES

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases.

see "attributes' tool for settings for this row

Guiding Principles

Solid is purpose-built to identify and develop the most promising approaches to address these diseases at all stages.

FOCUSED

We are focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases

PATIENT CENTRIC

We start with patients and their unmet needs.

COLLABORATIVE

We are working collectively with all stakeholders — industry, academia, government, and community — to advance our gene therapy candidates to better understand their potential to benefit patients.

CENTER OF EXCELLENCE

We are a catalyst bringing together the best knowledge to address all aspects of these diseases.

Core Values

Our values define, unite and strengthen our culture and reflect the individuals working at Solid. We have a collective drive to advance our mission as we strive to make a meaningful impact.